

## Bio/Disclosure Form

As a prospective planner or presenter/content expert/moderator, we need your help in protecting our learning environment from industry influence. Please complete the form below. All information will be kept confidential. Failure to comply with this request, will remove your ability to participate as planner/presenter/content expert/moderator for this activity. Attach additional pages, if needed.

\*Only moderators participating in education (i.e., serving on panels, Q&A, or impacting content in any manner) require a biodisclosure. Moderators serving solely as announcers and time managers do *not* require a biodisclosure.

Date Submitted (mm/dd/yyyy) 4/21/2023

### Role in Educational Activity (Check all that apply.)

☐ Planner ☒ Presenter/Content Expert ☐ Moderator\*

### Section 1: Demographic Data

|                              |                                                                 |
|------------------------------|-----------------------------------------------------------------|
| Name and credentials         | Paul DeLuca                                                     |
| Position and title           | Director of Emergency Management                                |
| Current employer and address | University of Chicago<br>5801 S. Ellis Ave<br>Chicago, IL 60637 |
| Phone                        | 773 702 3693                                                    |
| Email                        | pdeluca@uchicago.edu                                            |

### Section 2: Education and Expertise

Describe education specific to the educational activity listed above.

| Degree | Year | Institution                                    |
|--------|------|------------------------------------------------|
| MBA    | 2019 | University of Chicago Booth School of Business |
| MPH    | 2006 | University of Illinois at Chicago              |
|        |      |                                                |

Describe expertise specific to the educational activity listed above.

I oversee the University's Emergency Management and Business Continuity Programs. During the COVID-19 pandemic, I was heavily involved in the University's planning and response including creating and overseeing a contact tracing capability for the University. I am currently incorporating business resilience concepts into the overall preparedness strategy for the institution.

### Section 3: Conflict of Interest

**For Federal employees only:** For the past 24 months, I have been a federal employee and have been covered by all of the federal ethics rules, including the bribery and illegal gratuities statute (18 U.S.C. § 201), the criminal conflict of interests statutes (18 U.S.C. §§ 202-209), and the Standards of Ethical Conduct for Employees of the Executive Branch (5 C.F.R. Part 2635).

☐ Yes ☒ No

OR

**For Non-federal employees only:** Please disclose **all** financial **relationships** that you have had in the past 24 months with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients (e.g., device manufacturers, pharmaceutical companies, or bio-medical startups that have begun a governmental regulatory

approval process.) For any questions related to ineligible companies or any possible financial relationships, please contact your assigned CE Consultant.

NOTE: There is no minimum financial threshold; we ask that you disclose all financial relationships regardless of the amount with ineligible companies. Disclose the relationship regardless of the potential relevance of each relationship to the education. *Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, or ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual's institution receives the research grant and manages the funds.*

For the past 24 months, have you had **any** financial relationship with **any** ineligible company?

☐ Yes ☒ No

If yes, complete the table below.

| Name of Ineligible Company | Nature of Financial Relationship | Has the Relationship Ended? (Y/N) |
|----------------------------|----------------------------------|-----------------------------------|
|                            |                                  |                                   |
|                            |                                  |                                   |
|                            |                                  |                                   |

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>FOR DEVELOPERS ONLY:</b> Indicate the mitigation strategy used for the individual(s) who identified financial relationships with ineligible companies.                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Mitigation steps for <i>planner</i> (choose at least one)</b> <ul style="list-style-type: none"> <li><input type="checkbox"/> <b>Divest</b> the financial relationship</li> <li><input type="checkbox"/> <b>Recusal</b> from controlling aspects of planning and content with which there is a financial relationship</li> <li><input type="checkbox"/> <b>Peer review</b> of planning decisions by persons without relevant financial relationships</li> <li><input type="checkbox"/> Use <b>other methods</b> (please describe):</li> </ul> | <b>Mitigation steps for <i>presenter and others</i> (choose at least one)</b> <ul style="list-style-type: none"> <li><input type="checkbox"/> <b>Divest</b> the financial relationship</li> <li><input type="checkbox"/> <b>Peer review</b> of content by persons without relevant financial relationships</li> <li><input type="checkbox"/> <b>Attest</b> that clinical recommendations are evidence-based and free of commercial bias (e.g., peer-reviewed literature or adhering to evidence-based practice guidelines)</li> <li><input type="checkbox"/> Use <b>other methods</b> (please describe):</li> </ul> |

**\*\*If Planner only, Skip sections 4 and 5.**

#### Section 4: Unlabeled Use

Will your presentation(s) or content you contributed include any discussion of unlabeled use of commercial products or products for investigational use?

☐ Yes ☒ No

If Yes, please explain your use of unlabeled products or products under investigational use. Attach additional pages, if needed.

#### Section 5: Title of Presentation (Live) **OR** Content Provided

#### Section 6: Statement of Understanding

Completion of the line below serves as the electronic signature of the individual completing this form and attests to the accuracy of the information given above.

Paul DeLuca

4/21/2023

Typed Signature: Name and Credentials (Required)

Date